Oncology Research
Opportunities for effective drug discovery in oncology have never been better. Blueprints of the genetic and biochemical workings of cancer cells allow scientists in our laboratories to focus on promising targets for potential new therapeutic approaches. The impact of modern cancer genetics and immunotherapy on drug discovery is already changing the practice of medicine in oncology, with both biopharmaceuticals and small-molecules contributing to a growing repertoire of therapies.
Our fully integrated drug discovery centre in Vienna, Austria has more than 250 scientists with extensive capabilities in both small molecule and biotherapeutic discovery. A large number of collaborations with both academic partners and biotechnology companies are supporting our search for novel targets, biomarkers, drug candidates and treatment modalities.
Our Discovery Research focus is on
-
Cancer cell-directed therapies
-
Immune cell-directed therapies
-
-
Therapeutic Areas
-
Lung Cancer
-
Lung Cancer
Innovative research to improve lives for patients with cancer
-
Lung Cancer
For more than 20 years, we are taking cancer on by developing novel therapies with attention to two indication areas: lung cancer and gastrointestinal tumors.
-
Lung Cancer
At Boehringer Ingelheim, we believe this can be the generation that redefines many cancers as curable diseases. We want to be part of this transformation.
-
-
Lung Cancer
-
Lung Cancer
-
Lung Cancer
-
Oncology
-
Lung Cancer
An introduction to the work we’ve been doing with physicians and patients
-
Lung Cancer
Aoife McNamara, Irish Cancer Society, discusses the patient perspective on NSCLC treatment decisions
-
Backgrounder
Lung Cancer
-
Research & Development
Our new discovery research strategy aims at enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need.